Browsing Category
Pharma Industry News
4137 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How rare disease medicine access in Africa is moving from ad hoc supply to structured compliance-led programs
How Veld Pharmaceuticals and Chiesi are reshaping rare disease drug access in Africa through compliance-led programs. Read what this means for the sector.
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.
Could PP2A-targeted immunotherapy combinations improve outcomes in ovarian clear cell carcinoma?
Could PP2A-targeted immunotherapy reshape ovarian cancer treatment and Lixte’s valuation story? Read the executive analysis on what changes next.
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Novo Nordisk gets UK nod for single-dose Wegovy 7.2mg pen in obesity care
MHRA has approved the single-dose Wegovy 7.2mg pen for adults with obesity in the United Kingdom. Read what it means for patients and Novo Nordisk.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Kazia Therapeutics (NASDAQ: KZIA) bets on SETDB1 to widen oncology pipeline beyond paxalisib
Kazia Therapeutics has licensed a SETDB1 oncology platform from QIMR Berghofer. Read why the move could reshape KZIA’s pipeline strategy.
Hoth Therapeutics stock jumps on HT-VA data, but can HOTH turn preclinical promise into a real metabolic pipeline?
Hoth Therapeutics says HT-VA reprogrammed liver fat metabolism and outperformed semaglutide on key markers. Read what this means for HOTH now.
Who is really leading Indian pharma in 2026? The top 10 companies explained beyond the hype
Discover the top 10 pharma companies in India in 2026, who leads by revenue, reach, and strategy, and why the ranking is more complex than it looks.